 Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 L01.280.975.475.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- QALY
- Quality Adjusted Life Years
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in UAMS Profiles by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 2 | 2 | | 2019 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2016 | 0 | 4 | 4 | | 2015 | 1 | 3 | 4 | | 2014 | 1 | 1 | 2 | | 2013 | 0 | 1 | 1 | | 2012 | 1 | 2 | 3 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2001 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles over the past ten years.
-
Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Clin Ther. 2020 05; 42(5):860-872.e8.
-
Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 04; 23(4):451-460.
-
Manz KC, Waters TM, Clifton HE, Kocak M, Klesges RC, Talcott GW, Krukowski RA. Cost-Effectiveness of a Weight Loss Intervention: An Adaptation of the Look AHEAD Lifestyle Intervention in the US Military. Obesity (Silver Spring). 2020 01; 28(1):89-96.
-
Chen DY, Hsu PN, Tang CH, Claxton L, Valluri S, Gerber RA. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019 Aug; 22(8):777-787.
-
Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 07; 122(1):50-58.
-
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016 11; 44(10):1090-1101.
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
-
de Vlas SJ, Stolk WA, le Rutte EA, Hontelez JA, Bakker R, Blok DJ, Cai R, Houweling TA, Kulik MC, Lenk EJ, Luyendijk M, Matthijsse SM, Redekop WK, Wagenaar I, Jacobson J, Nagelkerke NJ, Richardus JH. Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004386.
-
Ferguson A, Yates C, Tilford JM. Value-based insurance designs in the treatment of mental health disorders. Am J Manag Care. 2016 Jan 01; 22(1):e38-44.
-
Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016; 19(3):243-58.
-
Payakachat N, Ali MM, Tilford JM. Can The EQ-5D Detect Meaningful Change? A Systematic Review. Pharmacoeconomics. 2015 Nov; 33(11):1137-54.
-
Tilford JM, Payakachat N, Kuhlthau KA, Pyne JM, Kovacs E, Bellando J, Williams DK, Brouwer WB, Frye RE. Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. J Autism Dev Disord. 2015 Nov; 45(11):3613-23.
-
Balakrishnan K, Bauman N, Chun RH, Darrow DH, Grimmer JF, Perkins JA, Richter GT, Shin JJ, Shivaram GM, Sidell DR, Elluru RG. Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations. Otolaryngol Head Neck Surg. 2015 May; 152(5):948-53.
-
Fortney JC, Pyne JM, Burgess JF. Population-level cost-effectiveness of implementing evidence-based practices into routine care. Health Serv Res. 2014 Dec; 49(6):1832-51.
-
Payakachat N, Tilford JM, Kuhlthau KA, van Exel NJ, Kovacs E, Bellando J, Pyne JM, Brouwer WB. Predicting health utilities for children with autism spectrum disorders. Autism Res. 2014 Dec; 7(6):649-63.
-
Wielage R, Bansal M, Wilson K, Klein R, Happich M. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine (Phila Pa 1976). 2013 May 15; 38(11):936-46.
-
Tilford JM, Payakachat N, Kovacs E, Pyne JM, Brouwer W, Nick TG, Bellando J, Kuhlthau KA. Preference-based health-related quality-of-life outcomes in children with autism spectrum disorders: a comparison of generic instruments. Pharmacoeconomics. 2012 Aug 01; 30(8):661-79.
-
Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012; 15(4):712-23.
-
Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. J Med Econ. 2012; 15(3):454-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|